GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Cell MedX Corp (OTCPK:CMXC) » Definitions » ROA %

Cell MedX (Cell MedX) ROA %

: 914.29% (As of Feb. 2024)
View and export this data going back to 2013. Start your Free Trial

ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Cell MedX's annualized Net Income for the quarter that ended in Feb. 2024 was $0.48 Mil. Cell MedX's average Total Assets over the quarter that ended in Feb. 2024 was $0.05 Mil. Therefore, Cell MedX's annualized ROA % for the quarter that ended in Feb. 2024 was 914.29%.

The historical rank and industry rank for Cell MedX's ROA % or its related term are showing as below:

CMXC' s ROA % Range Over the Past 10 Years
Min: -4300   Med: -815.66   Max: -316.67
Current: -741.15

During the past 12 years, Cell MedX's highest ROA % was -316.67%. The lowest was -4300.00%. And the median was -815.66%.

CMXC's ROA % is ranked worse than
99.08% of 868 companies
in the Medical Devices & Instruments industry
Industry Median: -1.64 vs CMXC: -741.15

Cell MedX ROA % Historical Data

The historical data trend for Cell MedX's ROA % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cell MedX Annual Data
Trend May14 May15 May16 May17 May18 May19 May20 May21 May22 May23
ROA %
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -767.80 -624.57 -863.51 -1,498.92 -687.50

Cell MedX Quarterly Data
May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24
ROA % Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2,484.21 -540.17 -373.33 -574.12 914.29

Competitive Comparison

For the Medical Devices subindustry, Cell MedX's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cell MedX ROA % Distribution

For the Medical Devices & Instruments industry and Healthcare sector, Cell MedX's ROA % distribution charts can be found below:

* The bar in red indicates where Cell MedX's ROA % falls into.



Cell MedX ROA % Calculation

Cell MedX's annualized ROA % for the fiscal year that ended in May. 2023 is calculated as:

ROA %=Net Income (A: May. 2023 )/( (Total Assets (A: May. 2022 )+Total Assets (A: May. 2023 ))/ count )
=-0.495/( (0.041+0.103)/ 2 )
=-0.495/0.072
=-687.50 %

Cell MedX's annualized ROA % for the quarter that ended in Feb. 2024 is calculated as:

ROA %=Net Income (Q: Feb. 2024 )/( (Total Assets (Q: Nov. 2023 )+Total Assets (Q: Feb. 2024 ))/ count )
=0.48/( (0.023+0.082)/ 2 )
=0.48/0.0525
=914.29 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Feb. 2024) net income data. ROA % is displayed in the 30-year financial page.


Cell MedX  (OTCPK:CMXC) ROA % Explanation

ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A bank’s ROA % is typically well under 2%.

Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:

ROA %(Q: Feb. 2024 )
=Net Income/Total Assets
=0.48/0.0525
=(Net Income / Revenue)*(Revenue / Total Assets)
=(0.48 / 0)*(0 / 0.0525)
=Net Margin %*Asset Turnover
=N/A %*0
=914.29 %

Note: The Net Income data used here is four times the quarterly (Feb. 2024) net income data. The Revenue data used here is four times the quarterly (Feb. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.

E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.


Cell MedX ROA % Related Terms

Thank you for viewing the detailed overview of Cell MedX's ROA % provided by GuruFocus.com. Please click on the following links to see related term pages.


Cell MedX (Cell MedX) Business Description

Traded in Other Exchanges
N/A
Address
123 W. Nye Lane, Suite 446, Carson City, NV, USA, 89706
Cell MedX Corp is an early stage development company focused on the discovery, development and, commercialization of therapeutic products for patients with diseases such as diabetes, by developing technologies to help manage the illness and related complications. The company's product portfolio consists of electromedical technologies, ebalance, and others.
Executives
Richard Jeffs 10 percent owner FLAT 7, 6 ENNISMORE GARDENS, LONDON X0 SW7 1NL
Dwayne Yaretz director, officer: Chief Executive Officer SUITE 1050 WEST PENDER STREET SUITE 2250, VANCOUVER A1 V6E 3S7
Bradley S Hargreaves 10 percent owner 904-1616 BAYSHORE DR, VANCOUVER A1 V6G3L1
Frank Mcenulty director, officer: CEO, CFO, Treas., Sec 4182 N. VIKING WAY, SUITE 216, LONG BEACH CA 90808-1475
Joao Dacosta director, officer: COO #810 - 789 WEST PENDER STREET, VANCOUVER A1 V6C 1H2
George Adams director 7535 CONSERVATION ROAD, GUELPH A6 N1H6J1
Terrance George Owen director, officer: CEO 635 FOURTH LINE (UNIT 1), OAKVILLE A6 L6L 5BO
John David Sanderson officer: Chief Medical Officer 9 ISLANDVIEW, IRVINE CA 92604
Yanika S Silina officer: CFO, Treasurer and Secretary 789 WEST PENDER STREET, UNIT 810, VANCOUVER A1 V6C 1H2
Jean M Arnett 10 percent owner 121 - 3989 HENNING DRIVE, BURNABY A1 V5C 6P8
Ean Kremer director, officer: Chief Technology Officer C/O PLANDEL RESOURCES, INC., 4575 DEAN MARTIN DRIVE, STE. 2206, LAS VEGAS NV 89103

Cell MedX (Cell MedX) Headlines

From GuruFocus

Cell MedX Insider Buys 22,500 Shares

By Kyle Ferguson Kyle Ferguson 11-11-2016